Sei Investments Co. Has $2.91 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sei Investments Co. boosted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 31.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 23,935 shares of the biotechnology company’s stock after acquiring an additional 5,764 shares during the period. Sei Investments Co.’s holdings in Sarepta Therapeutics were worth $2,910,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in SRPT. Wellington Management Group LLP boosted its holdings in shares of Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after acquiring an additional 665,087 shares during the period. Soros Fund Management LLC acquired a new stake in Sarepta Therapeutics during the 3rd quarter worth approximately $25,800,000. Swedbank AB bought a new stake in Sarepta Therapeutics in the 4th quarter valued at $16,706,000. Allspring Global Investments Holdings LLC grew its holdings in Sarepta Therapeutics by 16,717.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company’s stock valued at $10,602,000 after buying an additional 84,926 shares in the last quarter. Finally, Erste Asset Management GmbH increased its position in Sarepta Therapeutics by 11.3% during the 4th quarter. Erste Asset Management GmbH now owns 708,248 shares of the biotechnology company’s stock worth $86,116,000 after buying an additional 72,183 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Down 7.1 %

NASDAQ SRPT opened at $54.43 on Friday. The company has a market cap of $5.28 billion, a price-to-earnings ratio of 43.54 and a beta of 0.79. Sarepta Therapeutics, Inc. has a twelve month low of $54.26 and a twelve month high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The business’s fifty day moving average is $96.95 and its 200 day moving average is $113.78.

Insider Activity

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 7.70% of the company’s stock.

Wall Street Analyst Weigh In

SRPT has been the subject of a number of recent research reports. Needham & Company LLC reduced their target price on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating for the company in a research report on Thursday. Scotiabank decreased their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research report on Thursday, March 20th. HC Wainwright upgraded shares of Sarepta Therapeutics from a “sell” rating to a “neutral” rating and set a $75.00 price target for the company in a research report on Wednesday. Royal Bank of Canada downgraded Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $161.00 to $87.00 in a research report on Monday, March 31st. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a report on Wednesday, March 19th. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $163.18.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.